The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

Launched by NOVOSIBIRSK SCIENTIFIC RESEARCH INSTITUTE FOR CIRCULATORY PATHOLOGY · Jan 10, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a specific change in the GUCY1A3 gene, known as the rs7692387 polymorphism, affects the risk of heart-related problems after patients undergo coronary artery bypass grafting (CABG). CABG is a surgery to improve blood flow to the heart, and the study aims to see if people with this genetic change face a higher risk of complications like strokes or other cardiovascular events afterwards.

To participate in this trial, you need to be between the ages of 65 and 74 and have stable ischemic heart disease, which means your heart isn't getting enough blood but isn't in an emergency situation. You should also be scheduled for CABG surgery. However, if you are taking blood thinners, have low platelet counts, or are allergic to aspirin, you won't be eligible. If you join the study, you'll help researchers understand the relationship between genetics and heart health, contributing to better care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Stable ischemic disease 2- 4
• • CABG
• Exclusion Criteria:
• • the need to take any anticoagulants
• • thrombocytopenia
• • allergy to aspirin.